Abstract:1083 Introduction: High kidney uptake is a common feature of radiolabeled peptides, and this reduces detection sensitivity for lesions adjacent to kidneys and lowers maximum tolerated dose for radiotherapeutic application. The Met-Val-Lys (MVK) linker has been shown to reduce kidney uptake of 68Ga-labeled NOTA-conjugated peptides. The resulting lower kidney uptake was attributed to recognition and cleavage of the MVK sequence between MV by neprilysin (NEP), an endopeptidase found in abundance on the renal brush border lining. However, the use of NOTA chelator excludes application of such peptides for therapy using radioisotopes like 177Lu. For potential theranostic applications, DOTA is the preferred radiometal chelator. In this study, we evaluated if the MVK linker could be used to lower the kidney uptake of 68Ga-labeled DOTA-conjugated peptides as well. Methods: The DOTA conjugated linker (DOTA-AmBz-MVK(Ac)-OH; AmBz: 4-aminomethylbenzoyl), the expected cleaved metabolite DOTA-AmBz-Met-OH, and a PSMA-targeting ligand DOTA-AmBz-MVK(HTK01166)-OH were synthesized on solid-phase using standard Fmoc chemistry. All peptides were cleaved from resin with trifluoroacetic acid and purified by HPLC. Complexation with nonradioactive Ga and 68Ga was conducted in acetate (pH 4.5) and HEPES (pH 5.0) buffer, respectively. Renal proximal tubular brush-border membrane vesicles (BBMVs) were extracted from mouse kidneys. For NEP enzymatic recognition assay, Ga-68 labeled peptides were incubated with BBMVs (at 37 °C, 1 h) with/without the NEP inhibitor phosphoramidon (1 mg/well), and monitored by HPLC. In vivo stability was conducted in male NSG mice and the radiometabolites in blood (at 5 min post-injection, p.i.) and urine (15 min p.i.) were monitored by HPLC. PET/CT imaging and biodistribution studies were performed in mice bearing LnCap prostate cancer xenografts. Results: The DOTA-conjugated peptides and their Ga-complexes were successfully synthesized, and their identities were confirmed by MS analysis. Both in vitro and in vivo assays revealed complete cleavage (> 99%) of 68Ga-DOTA-AmBz-MVK(Ac)-OH with the expected 68Ga-DOTA-AmBz-Met-OH as the dominate radiometabolite (> 90%). The cleavage of 68Ga-DOTA-AmBz-MVK(Ac)-OH was inhibited (metabolite < 15%) in the presence of phosphoramidon in the in vitro enzyme assay. In vivo study showed that 68Ga-DOTA-AmBz-Met-OH was fast excreted from the body exclusively via the renal pathway with minimal kidney retention (<2.5 %ID/g). As for the PSMA-targeting ligand 68Ga-DOTA-AmBz-MVK(HTK01166)-OH, it was cleaved less effectively (79.6% intact) in the in vitro assay. The in vivo stability study also showed intact 68Ga-DOTA-AmBz-MVK(HTK01166)-OH (9%), the expected fragment 68Ga-DOTA-AmBz-Met-OH as a minor metabolite (35%) and an unidentified major radiometabolite (56%) in the blood. In the urine samples, only 68Ga-DOTA-AmBz-Met-OH (80%) and the intact tracer (20%) were detected. Imaging and biodistribution revealed lower tumor (3.98 %ID/g) and kidney (104 %ID/g) of 68Ga-DOTA-AmBz-MVK(HTK01166)-OH when compared to those of previously reported PSMA-targeting 68Ga-HTK01166 (14.1 and 147 %ID/g, respectively). Conclusions: We demonstrated that MVK can be inserted between DOTA and the targeting peptide sequences, and the resulting 68Ga-labeled peptides can be cleaved specifically between M-V by NEP. Due to very low kidney retention of the expected fragment, this strategy can be used to reduce kidney uptake of 68Ga-labeled DOTA-conjugated peptides, and potentially their 177Lu-labeled analogs for radiotherapy. High renal uptake of 68Ga-DOTA-AmBz-MVK(HTK01166)-OH could be due to renal retention of the unknown metabolite. This underscores the importance of conducting a thorough structure-activity-relationship study when applying this strategy to reduce kidney uptake of radiopeptides.

Differences in the Renal Accumulation of Radiogallium-Labeled (Glu)14 Peptides Containing Different Optical Isomers of Glutamic Acid

<SUP>68</SUP>Ga-Labeled GX1 Dimer: A Novel Probe for PET/Cerenkov Imaging Targeting Gastric Cancer

Structure-Activity Relationships and Pharmacokinetics of 111In-Labeled Glucagon-like Peptide-1 Receptor-Targeting Exendin-4 Derivatives Conjugated with Albumin Binder Moieties

Comparative Studies of Three 68Ga-Labeled [Des-Arg10]kallidin Derivatives for Imaging Bradykinin B1 Receptor Expression with PET.

A Comparative Study of Radiolabeled Bombesin Analogs for the PET Imaging of Prostate Cancer.

Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [111In]dtpa-Hegf and [111In]bz-Dtpa-hegf in Normal Mice

Development of an 111In-Labeled Glucagon-Like Peptide-1 Receptor-Targeting Exendin-4 Derivative that Exhibits Reduced Renal Uptake

Radiolabeled B9958 Derivatives for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography: Effect of the Radiolabel-Chelator Complex on Biodistribution and Tumor Uptake

Efficiency of succinylated gelatin and amino acid infusions for kidney uptake reduction of radiolabeled αvβ6-integrin targeting peptides: considerations on clinical safety profiles

Synthesis, Biodistribution and Quantitative Structure-Activity Relationship Studies of New 99mtc Labeled Pseudo-Peptide Complexes.

Radiolabeled Gamma-Aapeptides: A New Class of Pet Tracers

Synthesis of Labelled Small Peptide Complexes for Imaging Agents with Technetium-99M and Biodistribution in Mice.

Synthesis and Evaluation of Met-Val-Lys As a Cleavable Linker to Reduce Kidney Uptake of 68Ga-Labeled DOTA-conjugated Peptides

What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake

Linker effects on biological properties of 111In-labeled DTPA conjugates of a cyclic RGDfK dimer.

Synthesis and Evaluation of (68)Ga-Labeled DOTA-2-deoxy-D-glucosamine As a Potential Radiotracer in Μpet Imaging.

A comparison of the monomeric [68Ga]NODAGA-NGR and dimeric [68Ga]NOTA-(NGR)2 as aminopeptidase N ligand for positron emission tomography imaging in tumor-bearing mice

Evaluation of 111In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability

Preclinical study of an 18F-labeled glutamine derivative for cancer imaging.

Comparative evaluation of 68Ga-labelled TATEs: the impact of chelators on imaging

Biodistribution and Pharmacokinetics of 99tcm Labeled Carbohydrated Peptides in Mice Bearing Tumors